Most People Don't... But You Do!

The episode contains useful information about regenerative medicine and stem cell therapies, including specifics on umbilical cord tissue sourcing, concentration levels, and pricing ($5-15k range). However, much of the conversation devolves into motivational platitudes about discipline, mentorship, and the 'why' of entrepreneurship that are fairly generic. The regenerative medicine content is substantive but occupies roughly half the runtime; the other half is motivational filler that most B2B operators have heard before.

“We want to have the best, we want to have the best, most potent products on the market and the least expensive so that we can capture the market.”

“The whole, the sweet spot for what these products do is they regenerate and repair soft tissue defects.”

The direct-to-consumer, in-home delivery model for stem cell therapies is a legitimate business differentiation, and the explanation of umbilical cord tissue processing with higher concentration levels (150mg vs. 70mg standard) shows operational thinking. However, the broader narrative - mentorship, surrounding yourself with winners, discipline - is entirely conventional wisdom recycled through David Meltzer quotes. The core regenerative medicine space itself is not new, and Seth's positioning is incremental rather than contrarian.

“What kind of is. What sets that apart? I'm in the regenerative medicine field...we do concierge in home therapies rather than having brick and mortar clinics.”

“Because we're handling the process basically from A to Z, we have control over the margins.”

Seth Berge is a practitioner who has built two operating companies in regenerative medicine (Regenerative Revival and Precision Biologics) with 25+ employees and over 500k units sold last year. He has hands-on knowledge of the business model, product, and market. However, he is not a physician, researcher, or recognized authority in regenerative medicine; his credibility is operational/commercial rather than scientific. For a B2B audience, his sales and entrepreneurship background is relevant, but the guest lacks the depth of clinical or technical expertise one might expect for a specialized medical field.

“I'm 43 years old. I've been in entrepreneurship a little bit in sales since my early 20s.”

“Between my partners and I, we have, we did over 500,000 units of product last year.”

The episode includes concrete details on product sourcing (umbilical cord tissue from C-section births), tissue concentration (150mg vs. 70mg standard), product count (16 products), unit volumes (500k+ last year), pricing ($5-15k per patient, mostly), and geographic scope (all 50 states). The Joe Rogan rotator cuff example is referenced. However, there are few named customer examples, no specific clinical outcome data (success rates, healing timelines), no insurance coverage details, and minimal financial metrics (revenue, margin %, growth rate). Much of the specificity is product-focused rather than market-focused.

“We make about 16 products right now...we're like, okay, we want to make it ours be 150 milligrams of tissue weight per 1 milliliter...double the concentration level.”

“We did over 500,000 units of product last year.”

The host (Bart) asks reasonable open-ended questions and does follow up on the host's personal health narrative (neck discs, facet injections) to create relevance. However, questioning lacks sharpness and critical depth. The host rarely challenges Seth's claims, asks few hard questions about regulatory uncertainty, FDA approval status, outcomes, or competitive differentiation. There are soft moments where the host simply affirms and moves on (e.g., 'That's pretty darn cool, right?'). The conversation feels more like a platform-building interview than a rigorous B2B inquiry.

“Seth, I know you're not a doctor, but this is your world. Is it? And I know I'm not going to use any of the right words.”

“But, uh, as I'm thinking about that, for many people, including myself, that is worth saving up for.”